-

Global Smoking Cessation Market - Expected to Reach $63.99 Billion by 2026 Growing at a CAGR of 16.9% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Smoking Cessation Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Smoking Cessation market is expected to reach $63.99 billion by 2026 growing at a CAGR of 16.9% during 2018 to 2026.

Smoking cessation is the process of discontinuing tobacco smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. Nicotine withdrawal often makes the process of quitting difficult.

Some of the factors such as increasing number of smokers and stringent laws for smoking such as ban on smoking in public place are fuelling the market growth. However, a strict regulatory requirement for electronic cigarette as medical device is restraining the market growth.

Based on Therapy, Nicotine replacement therapy (NRT) segment has witnessed significant growth. Nicotine replacement therapy (NRT) reduces withdrawal feelings by giving a small controlled amount of nicotin but none of the other dangerous chemicals found in cigarettes. The small amount of nicotine helps satisfy craving for nicotine and reduces the urge to smoke.

The key vendors mentioned are British American Tobacco PLC, Dr. Reddy's Laboratories, Fontem Ventures, GlaxoSmithKline, GSK, Imperial Tobacco, Johnson & Johnson, Kimree Technology, Nicotek LLC, Njoy Inc, Novartis, Perrigo Company, Pfizer, Reynolds American Inc, Smoke Away, The Harvard Drug Group and VMR Products LLC.

Key Questions Answered in this Report:

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analyzed during the forecast period

Key Topics Covered:

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Smoking Cessation Market, By Product

5.1 Introduction

5.2 Chewing gum

5.3 Inhaler

5.4 Lozenge

5.5 Patch

5.6 Spray

5.7 Sublingual tablets

6 Global Smoking Cessation Market, By Therapy

6.1 Introduction

6.2 Nicotine replacement therapy(NRT)

6.3 Non-NRT therapy

6.4 E-Cigarette

7 Global Smoking Cessation Market, By End User

7.1 Introduction

7.2 Hospitals Pharmacies

7.3 Drug Stores

7.4 Retail Stores

7.5 Online Stores

8 Global Smoking Cessation Market, By Geography

8.1 North America

8.2 Europe

8.3 Asia Pacific

8.4 South America

8.5 Middle East & Africa

9 Strategic Benchmarking

10 Vendors Landscape

10.1 British American Tobacco PLC

10.2 Dr. Reddy's Laboratories

10.3 Fontem Ventures

10.4 GlaxoSmithKline

10.5 GSK

10.6 Imperial Tobacco

10.7 Johnson & Johnson

10.8 Kimree Technology

10.9 Nicotek LLC

10.10 Njoy Inc

10.11 Novartis

10.12 Perrigo Company

10.13 Pfizer

10.14 Reynolds American Inc

10.15 Smoke Away

10.16 The Harvard Drug Group

10.17 VMR Products LLC

For more information about this report visit https://www.researchandmarkets.com/r/tlhrgr

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Canada Diabetes Devices and Therapeutics Report 2025 | Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Canada Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to ResearchAndMarkets.com's offering. The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0%...

Societe Generale Digital Transformation Strategy Analysis Report 2025 | Initiatives, Partnerships, Product Launches, Investments, and Acquisitions - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: Societe Generale S.A. 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into company's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Societe Generale SA (Societe Generale) is a diversified financial services company. It has three business lines French Retail, Private Banking and Insurance; Global Bankin...

Asia-Pacific Diabetes Devices and Therapeutics Investment Report 2025 | Market to Grow by 8.8% Annually this Year Before Growing at a CAGR of 7.4% to 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to ResearchAndMarkets.com's offering. The diabetes market in Asia Pacific is expected to grow by 8.8% on annual basis to reach US$24.58 billion in 2025. The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 9.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAG...
Back to Newsroom